Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Summary

Streptococcus pneumoniae forms discrete non-purulent microscopic lesions in the heart. Outlined is the protocol for a murine model of cardiac microlesion formation. Instruction is provided on microlesion visualization using microscopy, discrimination between early and late microlesions, and methods to detect cardiac remodeling in hearts of convalescent animals.

Abstract

During bacteremia Streptococcus pneumoniae can translocate across the vascular endothelium into the myocardium and form discrete bacteria-filled microscopic lesions (microlesions) that are remarkable due to the absence of infiltrating immune cells. Due to their release of cardiotoxic products, S. pneumoniae within microlesions are thought to contribute to the heart failure that is frequently observed during fulminate invasive pneumococcal disease in adults. Herein is demonstrated a protocol for experimental mouse infection that leads to reproducible cardiac microlesion formation within 30 hr. Instruction is provided on microlesion identification in hematoxylin & eosin stained heart sections and the morphological distinctions between early and late microlesions are highlighted. Instruction is provided on a protocol for verification of S. pneumoniae within microlesions using antibodies against pneumococcal capsular polysaccharide and immunofluorescent microscopy. Last, a protocol for antibiotic intervention that rescues infected mice and for the detection and assessment of scar formation in the hearts of convalescent mice is provided. Together, these protocols will facilitate the investigation of the molecular mechanisms underlying pneumococcal cardiac invasion, cardiomyocyte death, cardiac remodeling as a result of exposure to S. pneumoniae, and the immune response to the pneumococci in the heart.

Introduction

Hospitalization of adults for community-acquired pneumonia (CAP) carries a documented risk for adverse cardiac events that contributes to mortality^1-4. In a recent study by Corrales-Medina et al. cardiac complications were found to be associated with and/or responsible for 27% of pneumonia-associated deaths³. Streptococcus pneumoniae (the pneumococcus), the most common cause of CAP and sepsis⁵, has been directly associated with adverse cardiac events in as many as 19% of admitted adult patients⁶. Adverse cardiac events associated with pneumonia include new or worsened congestive heart failure, arrhythmias, and myocardial infarction in order of decreasing frequency⁶.

In a recent PLoS Pathogens article by Brown et al., S. pneumoniae was found to be capable of translocation through the cardiac vascular endothelium, entry into the myocardium, and formation of discrete non-purulent microscopic lesions (microlesions) filled with bacteria in the ventricles during invasive pneumococcal disease (IPD)⁷. Evidence of cardiac microlesion formation was observed in cardiac samples from non-human primates and individuals who had succumbed to pneumococcal infection. Likewise, experimentally infected mice reproducibly developed cardiac microlesions. In mice, microlesion size and number was positively correlated with the duration and severity of bacteremia, levels of cardiac troponin in sera, and aberrant cardiac electrophysiology. Bacterial translocation into the heart was found to occur through the same mechanisms responsible for translocation of the pneumococcus across the blood-brain barrier and development of pneumococcal meningitis, i.e., Choline-binding protein A mediated invasion of vascular endothelial cells in a Laminin receptor and Platelet-activating factor receptor dependent manner⁸. Microlesion formation also required the pneumococcal pore-forming toxin pneumolysin that was found to kill cardiomyocytes⁷.

Pneumococcal cardiac microlesions are distinct from the purulent soft-tissue and cardiac abscesses that are caused by other Gram-positive bacteria including Staphylococcus aureus. These are characterized by a single foci of bacteria surrounded by neutrophils and fibrin deposition^9,10. Microlesions formed by S. pneumoniae are smaller in size, distributed throughout an affected heart, and lack immune cell infiltrates. During the early stages of infection, microlesions caused by S. pneumoniae appear as areas of damaged or inflamed tissue reminiscent of the pathological signs of cardiomyopathy. Some monocytes may be observed during this time, however their presence is short lived and lesions rapidly become necrotic in appearance and filled with bacteria while simultaneously continuing to grow in size until the death of the animal or antimicrobial intervention. Importantly, within 3 days of antibiotic intervention, profuse immune cell infiltration is observed at the former lesion site and this is accompanied by robust collagen deposition. Similar cardiac remodeling has been reported to occur following infarction along with lasting consequences on cardiac function^11-15. Thus, microlesions are a potential explanation for the adverse cardiac events that occur during IPD and possibly the increased incidence of cardiac-related mortality in convalescent individuals who have survived the disease episode.

Herein, instruction is provided on the experimental mouse model of IPD and cardiac lesion formation and visualization of cardiac microlesions at early and late stages of infection. The protocol for detection of collagen deposition in animals that have been saved by antimicrobial intervention is demonstrated. The goal of this article is to facilitate the research of other investigators on this important and novel pneumococcal pathology.

Access restricted. Please log in or start a trial to view this content.

Protocol

NOTE: All mouse experiments were reviewed and approved by the Institutional Animal Care and Use Committees at The University of Texas Health Science Center at San Antonio (protocol #13032-34-01C). Animal care and experimental protocols adhered to Public Law 89-544 (Animal Welfare Act) and its amendments, Public Health Services guidelines, and the Guide for the Care and Use of Laboratory Animals (U.S. Department of Health & Human Services).

1. Infection

1. Obtain BALB/c mice of both sexes between the ages of 10-12 weeks of age.
   NOTE: S. pneumoniae serotype 4 strain TIGR4 is a virulent clinical isolate that has been sequenced¹⁶.
2. Grow TIGR4 in Todd-Hewitt broth at 37 °C in 5% CO₂ until reaching an optical density (OD)₆₂₀ of 0.5 (corresponding to 1.0 x 10⁸ colony forming units [CFU]/ml). Pellet the pneumococcal culture by centrifugation for 10 min at 3,500 x g and remove the supernatant using a vacuum line. Suspend and dilute bacteria with sterile phosphate-buffered saline (PBS) to a final concentration of 1.0 x 10⁴ CFU/ml.
3. Using an induction chamber, anesthetize mice with 2.5% vaporized isoflurane in oxygen. Confirm anesthetized state by gentle toe pinch with blunt tweezers.
   1. Holding the anesthetized mouse by its scruff and upright with one hand, inject each mouse intraperitoneally (i.p.) with 100 µl of the S. pneumoniae suspension using a syringe with a 27-30 gauge needle (corresponding to a challenge dose of 1.0 x 10³ CFU). Place the mouse back in its cage. Mice typically awaken 30-40 sec after injection.
4. Allow the infection to proceed for at least 24 (early) or 30 (advanced) hr.
   1. Euthanize the mice by CO₂ asphyxiation. Perform cervical dislocation to ensure mouse has deceased. Euthanasia is further confirmed by removal of the heart in Step 1.6.
5. Disinfect the tail with an alcohol swab and snip a 2-3 mm section. Collect 2 µl of blood and serially dilute the blood 10-fold in PBS containing sodium heparin 1 U/ml five times. Plate serial dilutions on a tryptic soy blood agar plate and incubate overnight at 37 °C in 5% CO_2. The next day extrapolate from colony counts the level of bacteremia.
6. Immobilize the mouse in a supine position on a surgical platform. Spray the chest with 70% ethanol and pat dry. Using surgical scissors and forceps open the chest cavity, remove the rib cage, and transect the diaphragm to expose the heart and lungs. Using scissors cut the blood vessels connected to the heart and gently excise the heart with care to avoid bruising with forceps.
7. Rinse the heart with PBS and then place into tissue specimen collection cassettes such that coronal sections would be obtained during tissue sectioning. For paraffin embedding, place the cassettes in 10% buffered-formalin solution and the next day send for paraffin embedding.
   1. Alternatively flash freeze using O.C.T. Compound within a cryomold that has been placed on dry ice.

2. Visualization of Cardiac Lesions and Pneumococci within Lesions

1. Cut down paraffin-embedded heart sections such that the 4 chambers of the heart are visible in each tissue section. Cut slides at thickness of 5 µm.
2. Deparaffinize and stain slides with hematoxylin & eosin (H&E) using standard methods¹⁷.
3. View H&E stained cardiac sections using a light microscope at low (100X, 200X) and high (oil immersion: 400X, 1,000X) magnifications. Characterize hearts for the presence of microlesions in the myocardium. Here, acquire H&E images using a Zeiss Axioskop 2 microscope equipped with a 100X 1.3 numerical aperture Plan-NEOFLUAR objective.
   NOTE: At early stages cardiac lesions are discriminated by their differential colored appearance and in some instances the presence of immune cells (monocytes and granulocytes) what appear to be monocytes. In advanced lesions, particularly those seen at 30 hr, immune cells are absent and large vacuole-like lesions are observed in their place. It is important to note that while immune cell influx during the early stages of cardiac lesion development can occur it does not appear to be a requirement.

3. Immunofluorescent Microscopy for Pneumococci within Microlesions

1. Section heart in cryomolds with microtome to a thickness of 5 μm and place sections onto positively charged glass slides. Allow frozen cardiac sections to thaw and air dry. Fix sections for 10 min in 10% neutral buffered formalin (pH 6.8-7.2 at 25 °C).
2. Wash slides (3x) in PBS for 5 min, permeabilize for 15 min in 0.2% Triton X-100 in PBS, then wash again in PBS.
3. Block tissue section on slides with 10% goat serum in PBS for 1 hour.
4. Rinse slides with PBS, cover and incubate cardiac sections with rabbit anti-serotype 4 pneumococcus antiserum at 1:1,000 in PBS with 10% goat serum for 2 hr at 37 °C.
   NOTE: For negative controls investigators should use naive rabbit antiserum
5. After washing with PBS, cover and incubate sections with 10% goat serum-PBS with goat anti-rabbit FITC conjugated antibody at 1:2,000 for 30 min at 37 °C.
6. Following the manufacturer’s instruction, use DAPI (4',6- Diamidino-2-Phenylindole) at 5 mg/ml for visualization of eukaryotic nuclei. Wash and mount tissue sections with FluorSave.
7. Acquire fluorescent images using a confocal microscope system at both low and high magnification. Adjust the numerical aperture accordingly to obtain optimal results. Here, acquire fluorescent images using a confocal system with a 60X 1.42 numerical aperture objective.

4. Antibiotic Rescue of Septic Mice

1. Begin with mice infected i.p. with 1.0 x 10³ CFU of TIGR4 as previously indicated in step 1.
2. Beginning at 30 hr post-infection, administer pharmaceutical grade ampicillin i.p. (80 mg/kg body weight) in 100 µl saline every 12 hr for 36 hr. Collect hearts at the desired time point and process as described in step 1.6 for paraffin embedding and tissue, sectioning.

5. Collagen Deposition Detection

1. Using xylene and graded alcohol washes with deionized water, deparaffinize and hydrate tissue sections using standard methods¹⁷. Treat sections with aqueous 0.2% phosphomolybdic acid for 5 min and rinse with deionized water for 5 min.
2. Stain sections with 0.1% Sirius Red in picric acid for 2 hr at room temperature.
3. Wash sections in 0.01 N hydrochloric acid for 3 min and rinse using 70% ethanol for 1 min.
4. Dehydrate the sections using the identical but reverse order of washes to that outlined in 5.1, dehydrate cardiac sections in increasing and graded concentrations of ethanol then xylene.
5. Mount tissue sections with a mounting solution for microscopic evaluation.
6. To identify regions of collagen deposition, examine stained tissue sections for areas of deep read staining under low and high magnification using a light microscope. Any area within the ventricles of the heart that is red is an area where collagen has been deposited. Areas without this red stain are sites of healthy tissue lacking collagen deposition. Herein, acquire Picro Sirius Red stained images using a microscope equipped with a 20X 0.5 numerical aperture objective.
   NOTE: The atrium stains red in healthy tissues.

Access restricted. Please log in or start a trial to view this content.

Results

Visualization of Microlesions by H&E

Cardiac microlesions were observed in the ventricles of H&E stained cardiac sections from mice with IPD following their i.p. challenge with TIGR4. Figure 1 demonstrates the increase in size of these lesions between 24 and 30 hr post-infection (hpi), with greater number of hematoxylin-stained (i.e., purple-blue) pneumococci visible within the lesion. Microlesions were characterized by a vacuole-like morphology, dens...

Access restricted. Please log in or start a trial to view this content.

Discussion

In this report, a highly reproducible method to induce S. pneumoniae-mediated cardiac microlesions in mice during IPD and the techniques for their visualization is demonstrated. Mice are infected with a dose of bacteria that surpasses the immune system’s threshold for clearance, leading to high-grade bacteremia, similar to that which occurs during human sepsis, and leads to eventual bacterial translocation into the myocardium. For yet unknown reasons, S. pneumoniae in the heart is able to replicat...

Access restricted. Please log in or start a trial to view this content.

Materials

Name	Company	Catalog Number	Comments
Todd-Hewitt broth	Neogen	7161A
O.C.T Compound	Tissue-Tek (Sakura Finetek)	4583
Triton X-100	Fisher Scientific (Acros)	9002-93-1
Normal Goat Serum	Abcam	ab7481
anti-serotype 4 pneumococcus antiserum	Statens Serum Institut	16747
goat anti-rabbit FITC conjugated antibody	Jackson ImmunoResearch	111-096-144
DAPI	Invitrogen	D1306
Fluorsave	Millipore	345789
Permount	Fisher Scientific	S70104
Ampicillin	Sigma	A9393
phosphomolybdic acid 0.2%	Electron Microscopy Sciences	26357-01
0.1% Sirius Red in picric acid	Electron Microscopy Sciences	26357-02
0.01 N hydrochloric acid	Electron Microscopy Sciences	26357-03
Tissue Tack Microscope Slides	Polysciences, Inc	24216
Paralube Vet Ointment	Dechra	12920060
Hematoxylin and Eosin Staining Kit	unspeciified		Standard